Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Kracht PAM, Arends JE, van Erpecum KJ, Urbanus A, Willemse JA, Hoepelman AIM, Croes EA. Hepatol Med Policy. 2018 Sep 29;3:12. doi: 10.1186/s41124-018-0040-9.  h…

Drug consumption rooms (DCRs) as a setting to address hepatitis C - findings from an international online survey. Belackova V, Salmon AM, Schatz E, Jauncey M. Hepatol Med Policy. 2018 Aug 22;3:9. doi: 10.1186/s41124-018-0035-6. https://www.ncbi.n…

Hepatitis C virus prevention and care for drug injectors: the French approach. Delile JM, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J, Dhumeaux D. Hepatol Med Policy. 2018 Jun 5;3:7. doi: 10.1186/s41124-018-0033-8.  htt…

Oncogenic Signaling Induced by HCV Infection. Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Viruses. 2018 Oct 2;10(10). pii: E538. doi: 10.3390/v10100538. Review. https://www.mdpi.com/1999-4915/10/10/538

HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. Mavilia MG, Wu GY. J Clin Transl Hepatol. 2018 Sep 28;6(3):296-305. doi: 10.14218/JCTH.2018.00016. Epub 2018 Jul 6. Review. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC…

Pathways to ensure universal and affordable access to hepatitis C treatment. Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. BMC Med. 2018 Oct 9;16(1):175. doi: 10.1186/s12916-018-1162-z. https://www.ncbi.n…